Skip to main content
SpringerLink
Log in

Influence of Structural Variations in Peptidomimetic 4-Amidinophenylalanine-Derived Thrombin Inhibitors on Plasma Clearance and Biliary Excretion in Rats

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Systemic and hepato-biliary clearance of peptidomimetic thrombin inhibitors of the 4-amidinophenylalanine amide-type, derived from NAPAP (Nα-[2-naphthylsulfonyl-glycyl]-4-amidinophenylalanine-piperidide) by substituting Gly in P2 for natural and unnatural amino acids or by varying the C- and N-terminal moieties, resp., were investigated.

Methods. Concentrations of the compounds administered as intravenous bolus injection at a dose of 1 mg/kg to bile duct-cannulated rats were determined in plasma and bile samples collected over 4 hours using reversed-phase HPLC.

Results. NAPAP and the derivatives with additional charged groups are comparatively hydrophilic compounds. For NAPAP and most of the derivatives the biliary clearance accounted for a high percentage of the rapid systemic plasma clearance. Derivatives 2a-c with a second basic group in P2 position showed lower systemic and biliary clearance compared to NAPAP, whereas their cumulative biliary excretion after a period of 120 min was less affected. Bis-benzamidine derivatives 4a and 5 with the second amidino group in the N-terminal moiety had the lowest biliary clearance. Additional carboxylic groups reduced the systemic and biliary clearance only as free amidinophenylalanine carboxyl in 3a and 5. No influence compared to NAPAP was observed for 2d with a free carboxyl group in P2 position.

Conclusions. The weak correlation of the log P values of the compounds with the clearance parameters indicates the influence of structural variations, especially of charged groups, in this series of compounds rather than overall lipophilicity on hepato-biliary elimination mediated by hepatocellular transporters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. J. B. M. Rewinkel and A. E. P. Adang. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr. Pharm. Des. 5:1043–1075 (1999).

    Google Scholar 

  2. J. Hauptmann and J. Stürzebecher. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb. Res. 93:203–241 (1999).

    Google Scholar 

  3. M. R. Wiley and M. J. Fisher. Small molecule direct thrombin inhibitors. Expert. Opin. Ther. Patents 7:1265–1282 (1997).

    Google Scholar 

  4. P. E. J. Sanderson and A. M. Naylor-Olsen. Thrombin inhibitor design. Curr. Med. Chem. 5:289–304 (1998).

    Google Scholar 

  5. S. D. Kimball. Oral thrombin inhibitors: Challenges and progress. In A. C. G. Uprichard and K. P. Gallagher (eds.), Antithrombotics, Springer Verlag, Berlin Heidelberg New York, 1999 pp. 367–96.

    Google Scholar 

  6. K. Menear. Progress towards the discovery of orally active thrombin inhibitors. Curr. Med. Chem. 5:457–468 (1998).

    Google Scholar 

  7. J. Stürzebecher, F. Markwardt, B. Voigt, G. Wagner, and P. Walsmann. Cyclic amides of N?-arylsulfon-aminoacylated 4-amidinophenylalanine-tight binding inhibitors of thrombin. Thromb. Res. 29:635–642 (1983).

    Google Scholar 

  8. B. Kaiser, J. Hauptmann, A. Weiss, and F. Markwardt. Pharmacological charac-terization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta 44:1201–1210 (1985).

    Google Scholar 

  9. J. Hauptmann, B. Kaiser, M. Paintz, and F. Markwardt. Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor. Pharmazie 44:282–284 (1989).

    Google Scholar 

  10. J. Hauptmann, B. Kaiser, M. Paintz, and F. Markwardt. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbits and rats. Biomed. Biochim. Acta 46:445–453 (1987).

    Google Scholar 

  11. T. Steinmetzer, A. Schweinitz, S. Künzel, P. Wikström, J. Hauptmann, and J. Stürzebecher. Structure-activity relationships of new NAPAP-analogs. J. Enzyme Inhibit. 16:241–250 (2001).

    Google Scholar 

  12. B. Gabriel, M. T. Stubbs, A. Bergner, J. Hauptmann, W. Bode, J. Stürzebecher, and L. Moroder. Design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 41:4240–4250 (1998).

    Google Scholar 

  13. J. Stürzebecher, D. Prasa, J. Hauptmann, H. Vieweg, and P. Wikström. Synthesis and structure-activity relationships of potent thrombin inhibitors: Piperazides of 3-amidinophenylalanine.J. Med. Chem. 40:3091–3099 (1997).

    Google Scholar 

  14. G. Dickneite, D. Seiffge, K. H. Diehl, M. Reers, J. Czech, E. Weinmann, D. Hoffmann, and W. Stüber. Pharmacological characterization of a new 4-amidinophenylalanine thrombin-inhibitor (CRC 220). Thromb. Res. 77:357–368 (1995).

    Google Scholar 

  15. J. Hauptmann and B. Kaiser. In vitro and in vivo comparison of arginine-and benzamidine-derived highly potent synthetic thrombin inhibitors. Pharmazie 46:57–58 (1991).

    Google Scholar 

  16. B. Kaiser, J. Hauptmann, and F. Markwardt. Studies on toxicity and pharma-cokinetics of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile. Pharmazie 46:131–134 (1991).

    Google Scholar 

  17. M. J. Hursting, K. L. Alfor, J.-C. Becker, R. L. Brooks, J. L. Joffrion, G. D. Knappenberger, P. W. Kogan, T. P. Kogan, A. A. McKinney, and R. P. Schwarz. Novastan (Brand of argatroban): A small molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. 23:503–516 (1997).

    Google Scholar 

  18. U. G. Eriksson, L. Renberg, U. Bredberg, A.-C. Teger-Nilsson, and C. G. Regardh. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm. Drug Dispos. 19:55–64 (1998).

    Google Scholar 

  19. T. Lave, R. Portmann, G. Schenker, A. Gianni, A. Guenzi, M. A. Girometta, and M. Schmitt. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 51:85–91 (1999).

    Google Scholar 

  20. U. Eckhardt, W. Stüber, G. Dickneite, M. Reers, and E. Petzinger. First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver-interaction with bile acid transport systems. Biochem. Pharmacol. 52:85–96 (1996).

    Google Scholar 

  21. L. R. Bush. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. 9:247–263 (1991).

    Google Scholar 

  22. S. Ahmad, L. H. Yang, A. Ahsan, K. Fu, O. Iqbal, D. A. Hoppensteadt, B. E. Lewis, J. M. Walenga, and J. Fareed. Pharmacokinetics of argatroban in primates: Evidence on endogenous uptake. Int. Angiol. 19:126–134 (2000).

    Google Scholar 

  23. J. Q. Tran, R. A. Di Cicco, S. B. Sheth, M. Tucci, L. Peng, D. K. Jorkasky, M. J. Hursting, and L. J. Benincosa. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J. Clin. Pharmacol. 39: 513–519 (1999).

    Google Scholar 

  24. S. K. Swan and M. J. Hursting. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmaco-therapy 20:318–329 (2000).

    Google Scholar 

  25. K. Hilpert, J. Ackermann, D. W. Banner, A. Gast, K. Gubernator, P. Hadvary, L. Labler, K. Müller, G. Schmid, T. B. Tschopp, and H. Van de Waterbeemd. Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 37:3889–3901 (1994).

    Google Scholar 

  26. J. H. Proost, J. Roggeveld, J. M. Wierda, and D. K. Meijer. Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. J. Pharmacol. Exp. Ther. 282:715–726 (1997).

    Google Scholar 

  27. G. E. Blakey, I. A. Nestorov, P. A. Arundel, L. J. Aarons, and M. Rowland. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J. Pharmacokinet. Biopharm. 25:277–312 (1997).

    Google Scholar 

  28. J. Ishizaki, K. Yokogawa, E. Nakashima, and F. Ichimura. Relationships between the hepatic intrinsic clearance or blood cell-plasma partition coefficient in the rabbit and the lipophilicity of basic drugs. J. Pharm. Pharmacol. 49:768–772 (1997).

    Google Scholar 

  29. C. Neef and D. K. Meijer. Structure-pharmacokinetics relationship of quaternary ammonium compounds. Correlation of physicochemical and pharmacokinetic parameters. Naunyn-Schmiedeberg's Arch. Pharmacol. 328:111–118 (1984).

    Google Scholar 

  30. E. B. Hunter, S. P. Powers, L. J. Kost, D. I. Pinon, L. J. Miller, and N. F. LaRusso. Physicochemical determinants in hepatic extraction of small peptides. Hepatology 12:76–82 (1990).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Nordhäuser Str. 78, D-99089, Erfurt, Germany

    Jörg Hauptmann & Jörg Stürzebecher

  2. Department of Biochemistry and Biophysics, Friedrich Schiller University Jena, D-07743, Jena, Germany

    Torsten Steinmetzer

  3. Pentapharm Ltd., CH-4002, Basel, Switzerland

    Helmut Vieweg & Peter Wikström

Authors
  1. Jörg Hauptmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Torsten Steinmetzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helmut Vieweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Wikström
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jörg Stürzebecher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Hauptmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hauptmann, J., Steinmetzer, T., Vieweg, H. et al. Influence of Structural Variations in Peptidomimetic 4-Amidinophenylalanine-Derived Thrombin Inhibitors on Plasma Clearance and Biliary Excretion in Rats. Pharm Res 19, 1027–1033 (2002). https://doi.org/10.1023/A:1016426724831

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016426724831

Search

Navigation